MedTrace Logo

Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients

NCT06812728 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-02-19

No results posted yet for this study

Summary

A phase II clinical trial compared standard TNT (mFolfox6 and CRT) with preoperative chemoradiotherapy (CRT) with neoadjuvant chemotherapy (CT) containing mFolfirinox in patients with locally advanced rectal cancer.

Conditions

  • Rectum Cancer

Interventions

DRUG

mFOLFIRINOX

Neoadjuvant chemotherapy

DRUG

mFolfox6

Neoadjuvant chemotherapy

Sponsors & Collaborators

  • Menoufia University

    lead OTHER

Principal Investigators

  • Yostena Mekhail, MD,PhD · Menoufia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-25
Primary Completion
2027-01-25
Completion
2027-02-25

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06812728 on ClinicalTrials.gov